Lakefront Biotherapeutics Launches 50 Million Euros Share Repurchase Program
MT Newswires Live
Jun 10
Lakefront Biotherapeutics (LKFT) said Tuesday it has launched a share repurchase program of up to 50 million Euros, with repurchases to be conducted in the open market through December 31.
The program is being executed with Morgan Stanley as counterparty, the company said.
The buyback forms part of a broader authorization of up to $150 million in share repurchases tied to the company's transaction with Gilead, announced in March 2026, CFO Aaron Cox said.
Lakefront said it may suspend or terminate the program at any time.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.